Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 247-254, April 2005

Influence of psychotherapy attendance on buprenorphine treatment outcome

  • Iván D. Montoya, M.D., M.P.H.

      Affiliations

    • Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Rockville, MD 20892, USA
    • Corresponding Author InformationCorresponding author. Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, 6001 Executive Blvd. Bethesda, MD 20892-9551, USA. Tel.: +1-301-443-8639; fax: +1-301-443-2599.
    • ,
  • Jennifer R. Schroeder, Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Kenzie L. Preston, Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Lino Covi, M.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Annie Umbricht, M.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Carlo Contoreggi, M.D.

      Affiliations

    • Brain Imaging Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Paul J. Fudala, Ph.D.

      Affiliations

    • University of Pennsylvania School of Medicine and the Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • Rolley E. Johnson, Pharm.D.

      Affiliations

    • Reckitt Benckiser Pharmaceuticals, Inc. and Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
    • ,
  • David A. Gorelick, M.D., Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA

Received 22 August 2004; received in revised form 22 August 2004; accepted 11 January 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0740-5472(05)00016-4

doi:10.1016/j.jsat.2005.01.004

Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 247-254, April 2005

Article Tools

* Image Usage & Resolution